In a phase 3 study, Defencath (taurolidine and heparin) reduced catheter-related bloodstream infections by 71% compared to only heparin. The aqueous-based medication is approved for adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
